Health related quality of life (HRQoL) in childhood survivors of refractory GvHD treated with mesenchymal stromal cell infusions - a multi-center study

Health related quality of life (HRQoL) in childhood survivors of refractory GvHD treated with mesenchymal stromal cell infusions - a multi-center study - HRQoL after MSC treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32001

Enrollment

Registered

2008-05-08

Start date

2008-01-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beenmergtransplantatie bone marrow transplantations malignant diseases

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Patients who have undergone treatment with MSC*s for steroid refractory acute GvHD and are at least one month post infusion Anticipated life expectancy > 1 month. Signed informed consent by the patient and/or parent(s) or legal guardian(s). Aged between 2-18 years

Exclusion criteria

Exclusion criteria: Expected life expectancy

Design outcomes

Primary

Measure	Time frame
Health related quality of life, measured by the PEDS QL and clinical status assessment.	—

Secondary

Measure	Time frame
not applicable.	—

Countries

Netherlands

Outcome results